Synopsis

Source of validity: Scientific
Rating (out of 5): 5

Vitamin A (retinyl palmitate) is scientifically validated for use in the treatment and support of measles, especially in children. Numerous randomized controlled trials and meta-analyses have demonstrated that high-dose vitamin A supplementation can significantly reduce morbidity and mortality associated with measles, particularly in populations where vitamin A deficiency is common. The World Health Organization (WHO) and UNICEF recommend vitamin A supplementation for all children diagnosed with measles in areas where vitamin A deficiency may be present or among populations at risk. This intervention is based on evidence that measles can cause a rapid depletion of vitamin A stores, leading to complications such as blindness, severe diarrhea, and even death. Supplementation has been shown to reduce the risk of severe outcomes, including pneumonia and mortality, by improving immune function and supporting the integrity of mucosal surfaces. The typical regimen involves two doses of high-potency vitamin A given 24 hours apart. The evidence is rated as very strong (5/5) due to consistent findings in multiple large-scale studies and endorsement by leading health organizations. Thus, the use of vitamin A in measles is not based on tradition alone but on robust and reproducible scientific data.

More about Vitamin A (retinyl palmitate)
More about Measles

Other ingredients used for Measles

Other health conditions supported by Vitamin A (retinyl palmitate)

Products containing Vitamin A (retinyl palmitate)